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Abstract  
Pharmaceuticals are being used at an increasing rate, and end up in wastewater through 
excretion and disposal. They also end up in the effluent water of wastewater treatment plants 
because they are not specifically designed for pharmaceutical removal. Several studies suggest 
diverse negative effects on aquatic life that are exposed to these trace amounts of 
pharmaceuticals in their habitats. There is also a concern for human exposure in areas that utilize 
wastewater reuse, although there is limited study in this area. Despite these concerns, there are 
very few policies that address the issue of pharmaceutical pollution. The evaluation of the 
treatment methods of activated sludge, advanced membrane treatment, and constructed wetlands 
help to determine which of these options should be improved or replaced by different strategies. 
Additionally, there are other ways of solving this issue, such as developing more 
environmentally-friendly drugs and different ways of treating health problems.  
 
 Pharmaceuticals have been detected in effluent waters of wastewater treatment plants 
worldwide (Daughton 2004). This is because of their increased use (CDC 2010) as well as them 
not being targeted for removal during wastewater treatment. This issue should be of concern 
because these trace amounts have the potential to cause potentially harmful changes in aquatic 
life and possibly humans (EPA 2010). Current wastewater treatment has been researched to 
determine how well treatment plants in operation removal pharmaceutical compounds. Through 
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this research, conclusions can be drawn about whether to utilize current wastewater treatment 
plants or instead find other practical solutions.  
Pharmaceuticals are commonplace today in both prescription and over-the-counter (OTC) 
varieties. The FDA has approved over 100,000 drug compounds which make up over 10,000 
drug products. The latter number is actually less because of multiple brand names of drug 
products, but this amount is still striking. Additionally, there are drugs and drug compounds in 
use that have not been counted because they have not been approved by the FDA which should 
be taken into consideration when estimating the amount of pharmaceuticals in the waste stream 
(National Center for Biotechnology Information 2012). Based on a 2007 survey of U.S. 
residents, it can be estimated that almost half of the population has used at least one prescription 
drug in the past month, which breaks down to one out of every five children and 9 out of 10 
adults (Qiuping et al 2010). This is a high rate, especially considering that only prescription 
drugs were included in the survey. OTC drugs are used at a much higher rate, with another 
survey estimating that 79 percent of Americans have used at least one in the past year (Consumer 
Healthcare Products Association 2010).  
 In order for pharmaceuticals to work properly, they must be able to remain stable in the 
harsh conditions of the human body. This results in the inability of the compounds in many drugs 
to break down after they are excreted or otherwise disposed of. This is why pharmaceuticals are 
commonly found in wastewater both before and after going through treatment plants (Keil 2008). 
Pharmaceuticals may enter the water through excretion, disposal down drains, as well as through 
hospital and industry effluent. These routes encompass a range from the time they are being 
produced until their use or disposal. There are also many classes that pharmaceuticals can be 
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grouped into, such as antibiotics, antidepressants, anti-inflammatory, antiepileptic, as well as 
various hormones (EPA 2010). 
The concentrations of these pharmaceuticals are measured in micrograms or nanograms 
per liter, depending on equipment sensitivity. One microgram per liter is equivalent to one part 
per million, and one nanogram per liter is equivalent to one part per trillion. These seem too 
small to be significant, but even in these trace amounts, suspicions have arisen that they are 
changing the appearance and behavior of aquatic-dwelling organisms (Ternes 2004).  Aquatic 
life has a higher risk than humans of being affected because of the direct and constant exposure 
that they have to the contaminated water; their habitat may consist of effluent wastewater 
treatment plant water. Several different aquatic organisms have been studied, and it is important 
to realize that organisms may have different reactions to pharmaceutical compounds based on 
how their systems process them (EPA 2010).  Some compounds are hormones or mimic the 
properties of hormones, which are capable of feminizing or masculinizing fish (Ternes 2004).  In 
some cases, it has been observed that male fish have produced a protein that is typically only 
found in female fish because it is used for egg production (Gilbert 2012). The impact of neuro-
active pharmaceuticals has also been an area of study. Some of these studies suggest that this 
group of pharmaceuticals may alter the reproductive behavior of fathead minnows which could 
potentially decrease their populations. Additionally, the accumulation of neuro-active 
pharmaceutical metabolites in brain tissues has been observed in white suckers as well as brook 
trout, with the suggestion of negative impacts (EPA 2010).  Finally, another drug, the anti-
inflammatory, diclofenac, has shown to have damaged the gills and lungs of fish (Gilbert 2012). 
The “cocktail” effect is an important concept when discussing the possible effects of these 
pharmaceuticals. This phrase refers to the mixture of many different pharmaceuticals that are 
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present in the effluent water. These trace amounts of several different drugs make it difficult to 
predict exactly which drugs are affecting each other, and how this might contribute to the 
organisms that are exposed to this “cocktail” of drugs. The “cocktail” effect is a large reason 
why researching the impact pharmaceuticals have on aquatic life is very difficult (Ternes 2004).  
Human exposure to these trace levels of pharmaceuticals differs because of the lack of 
constant and long-term exposure to the contaminated water (EPA 2010). However, in some 
areas, water scarcity has resulted in the practice of wastewater reuse, and the drinking water has 
been detected to have parts per million or trillion levels of pharmaceuticals, including  iburofen, 
carbamazepine, and sulfamethoxazole (Luo et al 2014).  Wastewater reuse involves treating 
wastewater so that it can be consumed again instead of using the often scarce resource of 
groundwater. (Bixio et al 2006).  However, these wastewater treatment processes are often not 
designed to remove trace levels of pharmaceuticals (EPA 2010). One major study was executed 
to see if humans could potentially be affected by trace pharmaceutical levels. In this study, 
human embryos were exposed to a mix of 13 different pharmaceuticals meant to mimic the 
levels that would be found in the treated effluent wastewater (Potami et al 2006). This is an 
example of an attempt to account for the “cocktail” effect of the variety of pharmaceuticals that 
would be consumed in a scenario such as wastewater reuse. Physical changes to the shapes and 
appearance of the cells were observed in this study, indicating that these low levels carry 
potential to effect humans (Potami et al 2006). It is important to realize, however, that the results 
of this study are difficult to compare to interaction with reused wastewater in fully-developed 
humans.  
Despite limited research, there have been some pushes to recognize pharmaceutical 
contaminants in water sources. The Safe Drinking Water Act (SDWA) has done the most to 
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address this issue in the United States, although there are currently no formal US policies that 
deal with pharmaceuticals as water contaminants. The SDWA contains the Contaminant 
Candidate List (CCL), in which contaminants are periodically nominated for through a lengthy 
process. Being on this list does not guarantee regulation, but under the SDWA, the EPA is 
required to decide if at least five contaminants are to be regulated or not. The most recent list, the 
CCL 3, contains several contaminants that are found in pharmaceuticals. The contaminants 
17alpha-estradiol, Ethinyl Estradiol, estrone, estriol, Estradiol, equilin, and equilenin are all 
estrogenic hormones which are used in pharmaceuticals. This list also includes the antibiotic 
Erythromycin (EPA 2012b). Along with the CCL, the SDWA has proposed for the EPA to do 
more research regarding the environmental effects of pharmaceuticals in water bodies (Tiemann 
2010). 
Apart from the SDWA, the Proper Disposal of Prescription Drugs as well as a proposal 
by the Resource Conservation and Recovery Act (RCRA) somewhat address pharmaceuticals in 
wastewater. The Proper Disposal of Prescription Drugs deals with the consumer side of 
pharmaceuticals. It is a government document that was put forth in 2007 which clearly explained 
to consumers how to dispose of unwanted prescription drugs. It emphasized that flushing them 
down drains should not be done unless specifically dictated by the drug packaging. Although this 
government action was originally proposed for drug abuse prevention, if consumers follow the 
proposal, it could also apply to pharmaceutical presence in wastewater (Office of National Drug 
Control Policy 2007). The RCRA proposal in 2008 was to add hazardous pharmaceutical waste 
to the Universal Waste Program (EPA 2013b). This would have placed hazardous 
pharmaceutical waste in a category that governs the regulation of other widely generated wastes 
such as batteries, pesticides, and mercury-containing equipment (EPA 2012a). The original 
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proposal did not get public support, so it was instead replaced with new standards for hazardous 
pharmaceutical waste from these facilities. (EPA 2013b). This could potentially prevent the 
contribution of especially potentially harmful pharmaceuticals into the wastewater.  
Europe has somewhat addressed the issue of pharmaceutical regulation because of 
environmental concerns, but they also do not have complete policies. The EU Water Framework 
Directive is the main force for addressing water issues in Europe (European Commission 2014).  
Towards the end of 2012, the Water Framework Directive proposed the addition of 15 new 
contaminants to be placed on their list of priority substances, which included three 
pharmaceuticals. Two of these pharmaceuticals to be included were 17 alpha-ethinylestradiol 
(EE2), 17 beta-estradiol (E2), which are compounds that are used in contraceptive medications. 
The anti-inflammatory drug, diclofenac, was the third pharmaceutical included on the list. This 
proposed addition would have required that those pharmaceuticals be phased out within 20 years 
(Blöch). However, this proposal was never put into effect and was instead voted down by 
European Parliament. It was rejected because of the combination of projected high costs for 
implementation as well as uncertainty of whether these pharmaceuticals are actually doing harm. 
The voting members were likely swayed by the lobbying of both the water and pharmaceutical 
industries (Gilbert 2012).  In general, European environmental law operates on the Precautionary 
Principle, which essentially means that they carefully weigh all of the consequences before 
introducing substances into the environment. Pharmaceuticals are an exception to this because 
they are necessary for the health of many of their citizens. However, the mindset of the 
Precautionary Principle could lead Europe to become a leader of pharmaceutical change in 
regards to which compounds go into drugs as well as considering holistic options of treating 
health problems (Keil 2008).  
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One strategy for finding a solution to pharmaceuticals in effluent waters of wastewater 
treatment plants is through exploration of already-operating wastewater treatment plants. By 
evaluating how well certain wastewater treatment plants already remove pharmaceuticals, 
solutions for their improvement or other ways to navigate this issue can be more effectively 
devised. This is because time and money could potentially be saved by considering the 
wastewater treatment options which are already in operation instead of trying to think of 
completely new solutions. These diverse wastewater treatment methods include activated sludge, 
advanced membrane treatment, and constructed wetlands.  
Activated sludge is a common method for wastewater treatment; this is a biological 
treatment method in which microorganisms help degrade the organic compounds in the 
wastewater (Ternes 2004). Although it is fairly cheap to maintain this system, the major fault 
with using activated sludge is disposing of the waste it creates. The end product of this treatment 
method is a thick sludge that harbors the contaminants which have been removed from the 
wastewater (Deegan 2011). There is controversy as to how to dispose of this potentially 
dangerous product. Nutrients such as phosphorus are found in this sludge, so one solution that 
has been utilized is spreading it onto agricultural fields as a fertilizer. However, if the sludge is 
not treated for harmful contaminants such as heavy metals, health problems may result for 
people that come into contact with that land, or if it used to grow food for consumption. 
Incineration is another option, but then the issue comes about of how to prevent many of the 
contaminants from entering the atmosphere (George pp.151-168).  
Another wastewater treatment method is advanced membrane treatment, which has been 
recently appearing in areas such as Europe and the Middle East that are utilizing wastewater 
reuse as a result of water scarcity (Bixio et al 2006). This method is an additional treatment step 
7
Deziel: Pharmaceuticals in Wastewater Treatment Plant Effluent Waters
Published by University of Minnesota Morris Digital Well, 2014
to wastewater treatment which uses membranes to filter the water (Luo et al 2014). Two types of 
this membrane treatment are nanofiltration and reverse osmosis. Both of these processes are 
carried out through pressure changes and have the capacity to prevent certain contaminants from 
crossing over at the molecular level. However, there are some small differences between these 
two membrane treatment methods. One difference is that nanofiltration has pores in the 
membrane, whereas reverse osmosis consists of a semi-permeable membrane. Reverse osmosis 
uses hydraulic pressure which forces water from the side containing dissolved contaminants over 
to the dilution side instead of pores. In short, water is allowed to pass through the membrane, but 
not the solutes (EPA 2013a). One difficulty with implementing advanced membrane treatment is 
that is potentially costly to add another step to wastewater treatment when it is not absolutely 
vital. If a wastewater treatment plant is working perfectly fine, it may be difficult to convince 
leaders to see any value in investing in this additional step. The lack of research in the area of 
pharmaceutical contaminants in water, especially in regards to human effects may hinder social 
support because it may be difficult to see the worth of this treatment. Another difficulty of using 
membrane filtration systems is the brine that is produced with their use, which contains 
pharmaceutical and other contaminant residues that have been filtered out. Even though only a 
small amount is diluted into the effluent water, it is still a source of pollution.  Knowing that 
there is evidence for trace amounts of pharmaceuticals causing harm, this impact should be 
considered, because it would be best to remove as many of these pharmaceutical contaminants as 
possible (Radjenovic et al 2008).  
Constructed wetlands are a form of secondary wastewater treatment built with substrates 
and vegetation that imitate the way natural wetlands filter out impurities in water. There are 
many different designs that can be built along with various vegetation and substrate options. 
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However, there are some downfalls to this wastewater treatment method. Since a constructed 
wetland contains aspects found in a natural wetland, several species may be attracted, including 
those such as mosquitoes, which are seen as pests which may also carry disease. (Natural 
Resources Conservation Service)  As it is a step in treating wastewater, pathogens are likely to 
be present and could infect the vegetation, (Li et al 2014) but there is usually a greater concern of 
humans contracting infections. The constructed wetland would need to be in an area a good 
distance away from human habitation as well as have a large plot of land. The substrate and 
vegetation also need to be carefully selected for this wastewater treatment method to work 
effectively. In addition to this, vegetation is not as productive during cold winter months, so if a 
constructed wetland is built where cold weather occurs, it would not possess the same efficiency 
all year round (Natural Resources Conservation Service). 
Activated sludge treatment has the ability to break down certain pharmaceuticals to some 
degree. In general, there is a time range in which particular drugs degrade through activated 
sludge treatment. In 2-5 days, one antibiotic, sulfamethoxazole degrades to some degree, along 
with ibuprofen and acetylsalicylic acid, which is the breakdown product of Aspirin. However, 
some drugs generally need from 5-15 days to significantly degrade. These drugs include the anti-
inflammatory diclofenac and the antibiotic roxithromycin. Although these particular drugs 
experience degradation after some period of time, some are not generally shown to degrade even 
after a period of over 20 days. These include the pharmaceuticals carbamazepine, an anti-
epileptic, as well as diazepam, a psychoactive drug (Ternes 2004). The previous numbers are 
approximate, but one study in the United Kingdom looked at pharmaceutical removal 
efficiencies rates of a currently operating activated sludge wastewater treatment plant. The 
results indicated that removal rates of anti-inflammatory and analgesics were high. In particular, 
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Aspirin and salicyclic acid were almost completely removed at a rate of 98% and ibuprofen also 
had a high removal efficiency. Another noteworthy drug is the antiepileptic, gabapentin, which 
had an average removal efficiency of 84%. On the contrary of these high removal rates, one anti-
inflammatory, diclofenac, increased in concentration. This phenomenon is not unheard of and 
has been observed elsewhere with the pharmaceuticals erythromycin, an antibiotic, and 
carbamazepine, an anti-epileptic (Kasprzk-Hordern 2009). One reason this may occur is related 
to the breakdown products of the drugs as they pass through the human body. When drugs begin 
to break down in the human body, they may produce transformation products called metabolites. 
When biological treatment occurs, these breakdown products have the capacity to transform back 
into the original compounds, which are called the parent compounds. The presence of more 
parent compounds could yield test results of higher concentrations of that particular drug (Ternes 
2004).  
It would be economically viable to extend the sludge age of wastewater treatment plants that 
are already in operation. This could potentially result in the removal of more pharmaceuticals. 
However, a negative to this solution would be the aforementioned drugs that either do not 
decrease or instead increase in concentrations following activated sludge treatment. Many 
pharmaceuticals have not been extensively studied in regards to finding the most effective ways 
of removing them from our water (Kasprzk-Hordern 2009). Therefore, it would be the most 
logical to have concurrent research with a sludge age increase because the removal efficiencies 
of several pharmaceuticals with this wastewater treatment method are still fairly high. An 
increase in sludge age could also be a good temporary method until better treatment technologies 
are developed, or better ways of disposing of the massive amounts of sludge waste are devised. 
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A downfall to this strategy would be finding funding and support for pharmaceutical research 
and wastewater treatment development.    
 The different characteristics of membrane filtration determine the efficiency of 
pharmaceutical removal during the wastewater treatment method of advanced membrane 
treatment. Nanofiltration and reverse osmosis membranes both have structures that are very tight, 
but are still semi-permeable to some pharmaceuticals. In one study examining the removal of 
pharmaceuticals through this treatment method, it was found that the factor of polarity plays a 
large role in removal efficiencies. The negatively-charged surface of the nanofiltration 
membrane allowed the pharmaceuticals diclofenac and naproxen to be rejected and thus 
successfully removed by the membrane surface, whereas carbamazepine was only partially 
removed. However, when pharmaceuticals were uncharged, it was the physical and chemical 
properties of the compounds which determined how well they were retained by the nanofiltration 
method instead of the charge of the membrane surface (Luo et al 2014).   
The removal efficiencies of certain pharmaceuticals for these two advanced membrane 
treatment methods were compared in this study as well. Nanofiltration had the ability to slightly 
remove carbamazepine, which is a drug that activated sludge treatment does not usually remove. 
Additionally, 60% of diclofenac was removed by nanofiltration, (Luo et al 2014)  which is a 
much better removal efficiency compared to activated sludge treatment, in which it had a post-
treatment concentration increase (Kasprzk-Hordern 2009). Reverse osmosis fared better at 
removing diclofenac, with an efficiency of 95%. However, data was not collected for 
carbamazepine removal, so it is not known how reverse osmosis performs with that particular 
drug. The antibiotic, sulfamethoxazole had a 97% removal efficiency with reverse osmosis 
treatment, which is typically only found to degrade to a smaller degree with activated sludge 
11
Deziel: Pharmaceuticals in Wastewater Treatment Plant Effluent Waters
Published by University of Minnesota Morris Digital Well, 2014
treatment.  Reverse osmosis also resulted in an almost complete removal of ibuprofen. Reverse 
osmosis is a good solution and is overall effective for pharmaceutical removal, but it would be 
best to use among other treatment methods (Luo et al 2014). This treatment method would have 
a good place in a wastewater treatment plant as a polishing step to ensure better removal of 
pharmaceuticals.  
The mechanisms of substrate, plants, and microbes in constructed wetlands determine how 
well pharmaceuticals will be removed. A 2014 review compiled data on several constructed 
wetland treatment plants and discussed how substrates and plants contribute to pharmaceutical 
removal. Substrates use sorption processes which filter out certain pharmaceuticals. It was found 
that gravel worked well for drugs such as carbamazepine that had relatively high hydrophobicity 
but were not well removed through biological mechanisms. Another substrate, light expanded 
clay aggregate (LECA) was found to be good for sorption of acidic and neutral pharmaceutical 
compounds such as ibuprofen and carbamazepine. Granulated cork substrate was found to be 
able to remove a wider variety of pharmaceuticals. One consideration with substrate efficiencies 
is competition with pharmaceuticals as a result of the many different pharmaceuticals that are 
present in the wastewater. The sorption of certain pharmaceuticals may end up preventing the 
sorption of others. Plants aid in pharmaceutical removal because of their ability to take up certain 
drugs as well as their oxygen contribution to aid in biological pharmaceutical degradation. 
Pharmaceuticals with a moderate hydrophobicity and water solubility are able to pass through 
the membrane layer of plant cells as well as through to the plant cell fluids. Carbamazepine has 
been shown to be able to be taken up by the plant, Typha spp. because of these properties. On the 
contrary, diclofenac lacks these properties, and was found that it is difficult for it to be taken up 
by the plant, scirpus validus. When pharmaceuticals have been taken up by these plants, they are 
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further metabolized by processes within the plants. Plants also ensure that there is enough 
oxygen for the microorganisms which are needed for effective biological treatment. Their 
rhizosomes release oxygen which allow the microorganisms to break down pharmaceuticals 
more effectively. Biofilms are able to grow on the roots of plants, and have been demonstrated to 
largely remove ibuprofen. It is argued whether specific plants do better in general at 
pharmaceutical removal, and there is not enough information to determine if certain plants are 
more successful at this than others.  
The data analyzed in this review was taken from different countries, which included both 
urban and rural areas, and the average removal efficiencies for certain pharmaceuticals were 
calculated. Sulfamethoxazole had a high mean removal efficiency of 80%. The average removal 
efficiency of salicyclic acid ranged from 60-76%, whereas ibuprofen had a lower average of 
about 35-60% (Li et al 2014). This is a much lower removal efficiency than the reverse osmosis 
method, which almost completely removed ibuprofen (Luo et al 2004).  Carbamazepine was 
removed at an average efficiency of 15-20%, and diclofenac was removed at an average 
efficiency of 12-32% for constructed wetlands (Li et al 2014). In comparison to the other 
wastewater treatment methods, activated sludge treatment had a much higher removal efficiency 
of salicyclic acid at 98%. In the activated sludge treatment, diclofenac was the pharmaceutical 
which increased in concentrations (Kasprzk-Hordern 2009), so even though constructed wetlands 
may hardly remove a third of it, they still perform better for this particular drug. To further 
compare, nanofiltration treatment had a high removal efficiency of diclofenac of 60%, which is 
nowhere near perfect, but is much higher than what the constructed wetlands were able to 
remove. This leaves reverse osmosis as the best method for diclofenac removal at a high removal 
efficiency of 95% (Luo et al 2014). Carbamazepine removal has not usually been observed 
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during activated sludge treatment (Kasprzk-Hordern 2009) so the low removal efficiency in 
constructed wetlands is still superior (Li et al 2014). Additionally, nanofiltration fares about the 
same as constructed wetlands because it only slightly removes carbamazepine (Luo et al 2014).  
Constructed wetlands appear to be an economical solution when compared to more-
developed technology such as advanced membrane treatment because they are less costly to 
construct. This method would be a good solution for areas that have adequate space to build a 
constructed wetland, but do not have large amounts of money (Li et al 2004). More research 
would be very beneficial to this solution so that constructed wetlands could be built for the most 
effective removal of the pharmaceuticals that are of the most concern. This research would need 
to encompass the possible effects of certain pharmaceuticals as well as which plants and 
substrates perform the best. If more information is available on this, then it would be even easier 
for communities to build constructed wetlands because decisions on material choices could be 
more easily guided.   
 There are additional wastewater treatment possibilities that have not been entirely 
researched. An additional solution could be using membrane bioreactor treatment, which 
involves combining the steps of biological treatment and advanced membrane filtration (Luo et 
al 2014). Another possibility to be explored is the method of ecological sanitation. This often 
involves source separation, which is sequestering the urine and leaving it in a tank so that 
possible contaminants can degrade, and then using it as a valuable fertilizer. (Langergraber and 
Muellegger 2004). This could prevent some pharmaceuticals from entering the wastewater 
because many of them are found in urine. A 2007 study examined the active ingredients of 212 
pharmaceuticals to find out how much they are excreted through urine. It was found that there is 
large variability between groups of pharmaceuticals as well as within the groups themselves. 
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Therefore, it is difficult to generalize which groups of pharmaceuticals are readily excreted in 
urine. According to this study, acetylsalicyclic acid showed over 90% excretion through urine. 
Carbamazepine was excreted at 72%, and another antiepileptic drug, gabapentin is able to be 
completely excreted. Estrogenic compounds are excreted through urine at 73%. However, a drug 
in this class, ethinylestradiol, is an exception with only a 38% excretion by urine. In general, 
pharmaceuticals are more hydrophilic than pharmaceuticals that are excreted in feces, which are 
more lipophilic. Therefore, hydrophilic pharmaceuticals would be the targeted drugs if 
ecological sanitation was implemented. (Lienert et al 2007).  
Out of all of these solutions, there is not one that can be confirmed as the absolute best 
solution. A best solution would consider the environment, the people, and the economy in the 
particular area that is being looked at. A best solution would have a balance of giving benefit to 
all of these areas instead of sacrificing something in one area for the benefit of another. For 
example, it would not be the best solution to force everyone to discontinue the use of 
pharmaceuticals, because that would be neglecting the needs of many people that rely on them 
for their well-being. Similarly, using money that is needed for another problem such as poverty 
to invest in a high-technology wastewater treatment system would be economically and socially 
damaging, even if it would have environmental benefits.  
Gradual changes in the area of pharmaceutical use and attitudes could be a solution that 
would take into consideration the environment and the people, and in some ways economic 
stability.  Research could be invested in for the development of drugs that are less detrimental to 
and break down more easily in the environment. Additionally, a focus on a more holistic method 
of treating health problems could be beneficial because by looking for root causes of health 
problems, long-term healthcare costs could potentially decrease along with an increase in the 
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health of the people. Another solution could be investing in research to see which drugs are the 
most detrimental and then slowly phasing them out. This would work well in conjunction with 
developing more environmentally-friendly pharmaceuticals. Overall, it is important to consider 
the needs of the environment, the people, and the economy when trying to devise a solution for 
decreasing pharmaceutical contaminants in effluent wastewater (Keil 2008).  
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